Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abeona Therapeutics
(NQ:
ABEO
)
5.515
+0.395 (+7.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abeona Therapeutics
< Previous
1
2
Next >
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
August 14, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
August 13, 2024
CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient access
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
August 12, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
July 11, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
July 08, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
May 31, 2024
Via
AB Newswire
Exposures
Product Safety
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
May 15, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 03, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
May 02, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
May 01, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors
April 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Abeona Therapeutics Provides Regulatory Update on Pz-cel
April 22, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
March 18, 2024
- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
February 01, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $50 Million Credit Facility
January 08, 2024
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
November 27, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
November 13, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
September 26, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
September 12, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
September 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
August 30, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.